Page 12 - Relapsing Remitting Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

10-year Study Links Worse Outcomes to Smoking By RRMS Patients | Study Examines Effects of Smoking and Multiple Sclerosis

10-year Study Links Worse Outcomes to Smoking By RRMS Patients | Study Examines Effects of Smoking and Multiple Sclerosis
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Long term gray matter atrophyClinical disabilityRelapsing remitting multiple sclerosis

DGAP-News: Immunic, Inc : Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational N

Issuer: Immunic, Inc. / Key word(s): Scientific publication/Study results Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting

United statesEdna kaplanPaula schwartzJessica breuRobertj foxDaniel vittExchange commissionNeurologic instituteMellen centerRx communications groupImmunic incDistribution servicesAnnounces publicationData from its phaseVidofludimus calciumRelapsing remitting multiple sclerosis

Novel Drug Tied to Slowed Disease Progression in Relapsing MS

The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.

United statesRocky mountainNew yorkStony brookNational harborEnrique alvarezPatriciak coyleMichaels weissConsortium of multiple sclerosis centersUniversity of coloradoDepartment of neurologyUblituximab tg therapeutics incDrug administrationStony brook university medical centerMountain multiple sclerosis centerRocky mountain multiple sclerosis center

Novel Drug Safe, Effective in Relapsing MS: 2-Year Data

The investigational evobrutinib, an Bruton s tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.

New yorkUnited statesStony brookNational harborPatriciak coyleJerrys wolinskyHanne crossConsortium of multiple sclerosis centersDepartment of neurologyMcgovern medical schoolTrotter multiple sclerosis centerStony brook university medical centerTexas health science centerMedscape medicalMultiple sclerosis centersMedscape medical news

RRMS Patients More Likely to Adhere to Treatment if Married, Educated

RRMS Patients More Likely to Adhere to Treatment if Married, Educated
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Disease modifying treatmentsRelapsing remitting multiple sclerosisProspective cohort studyMultiple sclerosisExpanded disability status scale